In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Esteve: Aspiring to Innovation

Executive Summary

Changing global dynamics, and increasing price pressures in Spain, are compelling private Esteve to change its strategy and its structure. The company feels a need to be bolder and more efficient than before. The firm continues leveraging its traditional strength, helping Big Pharmas market. But lately it has also allied with US biotechs, paying more for exclusive rights to novel products. It's risky, though: two drug candidates it hoped to get failed recently. Now, making research pay off is a top priority for Esteve, which views itself as having a research-oriented culture, although its only successful drug was launched 20 years ago. The company's new strategy heightens risks and difficulties, but the owners feel they have little choice in the increasingly cost-controlled Spanish market. As a private company, Esteve can afford to place the bet and strive for success.

You may also be interested in...



MedPointe's Private Dilemma

MedPointe was born via the leveraged buy-out of an old, private pharmaceutical company, Carter-Wallace. Accepting financial strictures was part of the deal; the company must remain profitable. This increases the challenge for the "founders," seasoned pharma execs intent on leveraging the infrastructure they overhauled, to created an in-licensing based marketing powerhouse. Beyond competing with bigger pharma marketers, management's challenge remains bringing in new assets affordably.

Surfaxin: Epitomizing Esteve

The progress of Esteve's lead compound Surfaxin illustrates how the Spanish group is building a robust, yet risk-controlled pipeline to supplement its co-marketing activities. The compound may also become the first marketed drug in which Esteve played an active development role, and bears testament to the private group's partnering appeal.

Spain Drives Bentley

Spain's patent situation has allowed Bentley Pharmaceuticals to thrive there by marketing both traditional generics and copies of patented products. But this Spanish loophole won't last forever.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel